New treatment vulnerability found in aggressive, hormone-resistant prostate cancer
Researchers from the Rubin Lab and international collaborators have identified a new treatment vulnerability in a particularly aggressive form of advanced prostate cancer that no longer responds to hormone therapy. Using so-called proteolysis-targeting chimeras (PROTACs) to degrade SWI/SNF chromatin-remodelling proteins, the team showed that a “double-negative”, WNT-driven subtype of castration-resistant prostate cancer is highly sensitive to this epigenetic approach in patient-derived organoids and mouse models.